Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07382076 · ClinicalTrials.gov registry record
Clinical Evaluation of the i-STAT ACTpro Cartridge in an Adult Population
A clinical trial of Activated Clotting Time, sponsored by Abbott Point of Care.
- Active
- Registry status
- 500
- Enrollment target
- 11
- Study locations
NCT07382076: Active study of Activated Clotting Time, sponsored by Abbott Point of Care.
NCT07382076 is a study of Activated Clotting Time that is active but no longer recruiting, run by Abbott Point of Care. The registered enrollment target is 500 participants. The trial reports 11 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07382076, a study of Activated Clotting Time, is active but no longer recruiting, sponsored by Abbott Point of Care.
- ACTIVE NOT RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 11
- Study locations
Study Summary
Measuring Activated Clotting Time (ACT) using the i-STAT ACTpro cartridge on the i-STAT 1 analyzer compared to a comparator device.
Primary Outcome
Compare ACT test results obtained from the ACTpro cartridge using the i-STAT 1 analyzer with the ACT test result obtained from a comparator device using whole blood specimens.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Blood draw
Study Locations (11)
Pennsylvania
- Penn State University Hershey Medical Center - Hershey
- Thomas Jefferson University - Philadelphia
Arizona
- Dignity Health Chandler Regional Medical Center - Chandler
California
- University of California at San Francisco - San Francisco
District of Columbia
- George Washington University - Washington D.C.
Kentucky
- Kentucky Clinical Trials Laboratory - Louisville
Maryland
- University of Maryland - Baltimore
Minnesota
- Minneapolis Heart Institute - Minneapolis
Missouri
- Washington University - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2023-12-15 |
| Est. Completion | 2026-03-30 |
What the registry record for NCT07382076 still lists
NCT07382076 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Activated Clotting Time appearing as the primary indexed condition, and to 1 intervention - of which Blood draw is the first listed.
NCT07382076 lists 11 locations in 10 states (Pennsylvania, Arizona, California).
Frequently Asked Questions
What is clinical trial NCT07382076 about?
NCT07382076 is a clinical study titled "Clinical Evaluation of the i-STAT ACTpro Cartridge in an Adult Population". Measuring Activated Clotting Time (ACT) using the i-STAT ACTpro cartridge on the i-STAT 1 analyzer compared to a comparator device.
What is the current status of trial NCT07382076?
This trial is currently active not recruiting. The enrollment target is 500 participants. The study started on 2023-12-15. Estimated completion is 2026-03-30.
What conditions does trial NCT07382076 study?
This clinical trial studies the following conditions: Activated Clotting Time.
What interventions are being tested in trial NCT07382076?
The interventions under investigation include: Blood draw (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07382076?
This trial is sponsored by Abbott Point of Care, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07382076 being conducted?
This trial has 11 study locations across Arizona, California, District of Columbia, Kentucky, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI